108 results
6-K
EX-99.1
ARGX
Argen X SE
16 Apr 24
ADHERE data show VYVGART® Hytrulo has potential to be first advancement for CIDP patients in 30 years
6:05am
of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP
6-K
EX-99.1
ARGX
Argen X SE
27 Mar 24
Current report (foreign)
6:14am
. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs
6-K
EX-99.1
ARGX
Argen X SE
27 Mar 24
Current report (foreign)
6:07am
researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel
6-K
EX-99.1
ARGX
Argen X SE
26 Mar 24
Regulatory decision in Japan represents first global approval for VYVGART in ITP
6:05am
collaboration to bring real innovation for the millions of patients around the world living with rare autoimmune disease. And our work has only just … through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody
6-K
EX-99.1
48ksskj
21 Mar 24
Current report (foreign)
6:07am
6-K
EX-99.1
xez0kpq8etuq4n2sq
8 Mar 24
ADHERE data presentation will highlight first potential innovation for CIDP patients in 30 years
6:05am
6-K
EX-99.2
s0pvo b5hr0zzblq
29 Feb 24
Current report (foreign)
4:04pm
6-K
EX-99.1
8j25j2yno2xx aumxe
29 Feb 24
Current report (foreign)
4:04pm
6-K
EX-99.1
twhrip ev2mi
20 Feb 24
If approved, VYVGART® Hytrulo will be the first neonatal Fc receptor (FcRn) blocker to treat CIDP
6:06am
6-K
EX-99.1
rr89d4gilw9rs3fudh
18 Jan 24
Current report (foreign)
6:10am
6-K
EX-99.1
zu3pl28hhwh0irm
8 Jan 24
Reported $1.2 billion in preliminary* full-year 2023 global net product sales
6:06am
6-K
EX-99.2
j7mti37jscbrrvp
8 Jan 24
Reported $1.2 billion in preliminary* full-year 2023 global net product sales
6:06am
6-K
EX-99.1
b7ykmxgf caux4v8
20 Dec 23
Current report (foreign)
6:00am
6-K
EX-99.1
m9z7lgjh4zhl
28 Nov 23
Current report (foreign)
6:01am
6-K
EX-99.1
rgr0fpuw56t3cqcv ck1
17 Nov 23
VYVGART® is now approved for both intravenous (IV) and self-administered subcutaneous (SC) use in Europe
6:01am
6-K
EX-99.1
529uvx7 4dj
1 Nov 23
Patients treated with VYVGART experienced consistent improvements on key quality of life measures based on long-term gMG extension data
4:01pm
6-K
EX-99.2
5rp4d
31 Oct 23
Current report (foreign)
9:14am
6-K
EX-99.1
iw8s85m
31 Oct 23
Current report (foreign)
9:14am
6-K
EX-99.1
o0v2n3j4kk6g3oet
21 Sep 23
Current report (foreign)
8:38am